经皮外周神经刺激治疗截肢后慢性神经病理性疼痛:多中心随机安慰剂对照试验
主要终点显示PNS组第1-4周≥50%疼痛缓解比例显著高于安慰剂组(58% vs 14%,p=0.037)。
要点
- 经皮PNS可显著提高截肢后慢性神经病理性疼痛≥50%缓解率。
- 8周治疗时PNS组疼痛和疼痛干扰≥50%改善比例均显著优于安慰剂。
- 部分完成12个月随访者仍报告≥50%疼痛缓解,提示疗效可能持久。
核心结论
- 经皮PNS治疗可能为截肢后慢性神经病理性疼痛提供持久的临床显著疼痛缓解并改善功能障碍。
研究设计与样本
- 受试者超声引导下植入经皮PNS导线,随机接受PNS或安慰剂4周,安慰剂组随后交叉接受PNS 4周。
主要发现
- 第1-4周PNS组≥50%平均截肢后疼痛缓解比例为58%(7/12),安慰剂组为14%(2/14),p=0.037。
- 8周治疗时PNS组≥50%疼痛缓解比例为67%(8/12),安慰剂组为14%(2/14),p=0.014。
- 8周治疗时PNS组≥50%疼痛干扰改善比例为80%(8/10),安慰剂组为15%(2/13),p=0.003。
- 截至分析时完成12个月随访的5例PNS受试者中4例报告≥50%疼痛缓解。
临床怎么用
- 对于下肢截肢后慢性神经病理性疼痛患者,可考虑经皮PNS作为治疗选项。
- 治疗决策需结合超声引导植入技术和患者个体情况。
局限性
- 长期随访数据有限,仅报告5例完成12个月随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Chronic neuropathic pain is a common challenging condition following amputation. Recent research demonstrated the feasibility of percutaneously implanting fine-wire coiled peripheral nerve stimulation (PNS) leads in proximity to the sciatic and femoral nerves for postamputation pain. A multicenter, double-blinded, randomized, placebo-controlled study collected data on the safety and effectiveness of percutaneous PNS for chronic neuropathic pain following amputation. METHODS: Twenty-eight lower extremity amputees with postamputation pain were enrolled. Subjects underwent ultrasound-guided implantation of percutaneous PNS leads and were randomized to receive PNS or placebo for 4 weeks. The placebo group then crossed over and all subjects received PNS for four additional weeks. The primary efficacy endpoint evaluated the proportion of subjects reporting ≥50% pain reduction during weeks 1-4. RESULTS: A significantly greater proportion of subjects receiving PNS (n=7/12, 58%, p=0.037) demonstrated ≥50% reductions in average postamputation pain during weeks 1-4 compared with subjects receiving placebo (n=2/14, 14%). Two subjects were excluded from efficacy analysis due to eligibility changes. Significantly greater proportions of PNS subjects also reported ≥50% reductions in pain (n=8/12, 67%, p=0.014) and pain interference (n=8/10, 80%, p=0.003) after 8 weeks of therapy compared with subjects receiving placebo (pain: n=2/14, 14%; pain interference: n=2/13, 15%). Prospective follow-up is ongoing; four of five PNS subjects who have completed 12-month follow-up to date reported ≥50% pain relief. CONCLUSIONS: This work demonstrates that percutaneous PNS therapy may provide enduring clinically significant pain relief and improve disability in patients with chronic neuropathic postamputation pain. TRIAL REGISTRATION NUMBER: NCT01996254.
引用
- Gilmore C, Ilfeld B, Rosenow J, et al. Percutaneous peripheral nerve stimulation for the treatment of chronic neuropathic postamputation pain: a multicenter, randomized, placebo-controlled trial. Reg Anesth Pain Med. 2019. PMID: 30954936. doi:10.1136/rapm-2018-100109
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。